IIM
PVLA

INTECH Investment Management’s Palvella Therapeutics PVLA Stock Holding History

INTECH Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$246K Sell
1,974
-1,495
-43% -$156K ﹤0.01% 1656
2025
Q4 		$363K Sell
3,469
-659
-16% -$56.2K ﹤0.01% 1661
2025
Q3 		$259K Buy
+4,128
New +$184K ﹤0.01% 1912

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

INTECH Investment Management's PVLA Position: Q1 2026 in Review

INTECH Investment Management reduced its Palvella Therapeutics (PVLA) stake by 43% in Q1 2026, selling an estimated $156K and leaving 1,974 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1656.

INTECH Investment Management first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. The position peaked at $363K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • INTECH Investment Management held 1,974 shares of Palvella Therapeutics worth $246K as of Q1 2026.
  • INTECH Investment Management sold 1,495 Palvella Therapeutics shares in Q1 2026, an estimated $156K.
  • Palvella Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1656 holding.
  • INTECH Investment Management first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • INTECH Investment Management's Palvella Therapeutics position peaked at $363K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.